Skip to main content

Rapt Therapeutics, Inc. (RAPT)

NASDAQ: RAPT · IEX Real-Time Price · USD
31.16 -1.58 (-4.83%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap920.66M
Revenue (ttm)4.36M
Net Income (ttm)-64.01M
Shares Out29.55M
EPS (ttm)-2.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume130,040
Open35.93
Previous Close32.74
Day's Range30.11 - 32.50
52-Week Range14.89 - 43.26
Beta0.11
AnalystsBuy
Price Target60.29 (+93.5%)
Earnings DateNov 15, 2021

About RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193...

IndustryBiotechnology
IPO DateOct 31, 2019
CEOBrian Wong
Employees81
Stock ExchangeNASDAQ
Ticker SymbolRAPT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for RAPT stock is "Buy." The 12-month stock price forecast is 60.29, which is an increase of 93.49% from the latest price.

Price Target
$60.29
(93.49% upside)
Analyst Consensus: Buy

News

Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -5.00% and -33.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

RAPT Therapeutics Reports Third Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

2 weeks ago - GlobeNewsWire

RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

2 weeks ago - GlobeNewsWire

Rapt Therapeutics (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Rapt Therapeutics (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

RAPT Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

2 weeks ago - GlobeNewsWire

RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease S...

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

1 month ago - GlobeNewsWire

RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the ...

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing an...

1 month ago - GlobeNewsWire

RAPT Therapeutics to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing an...

2 months ago - GlobeNewsWire

RAPT THERAPTICS (RAPT) Reports Q2 Loss, Lags Revenue Estimates

RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of -1.61% and -39.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

RAPT Therapeutics Reports Second Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

3 months ago - GlobeNewsWire

Analysts Estimate RAPT THERAPTICS (RAPT) to Report a Decline in Earnings: What to Look Out for

RAPT THERAPTICS (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to P...

SOUTH SAN FRANCISCO, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

5 months ago - GlobeNewsWire

RAPT Reports Positive Data From Atopic Dermatitis Study

RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.

Other symbols:REGNRGENSNY
5 months ago - Zacks Investment Research

RAPT Therapeutics Raises $125M Via Equity At 6% Discount

RAPT Therapeutics Inc (NASDAQ: RAPT) has priced its previously announced underwritten public offering of 3.8 million shares at $33/share. The price represents a 6% discount from last the close price of ...

5 months ago - Benzinga

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

5 months ago - GlobeNewsWire

RAPT Therapeutics (RAPT) is in Overbought Territory: What's Next?

RAPT Therapeutics (RAPT) has moved higher as of late, but there could definitely be trouble on the horizon for this company

5 months ago - Zacks Investment Research

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

5 months ago - GlobeNewsWire

Why RAPT Therapeutics Stock Is Surging Today

RAPT Therapeutics Inc (NASDAQ:RAPT) shares are trading higher by 95% at $36.19 after the company reported topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as mono...

5 months ago - Benzinga

Why RAPT Therapeutics Stock Is Crushing It Today

The company reported great results from an early-stage study of its experimental atopic dermatitis drug.

5 months ago - The Motley Fool

RAPT Stock: The Big Study News That Has RAPT Therapeutics Rocketing 100%+

RAPT Therapeutics (RAPT) stock is rocketing higher on Monday thanks to positive results from a recent clinical trial of RPT193. The post RAPT Stock: The Big Study News That Has RAPT Therapeutics Rocketi...

Other symbols:AMCRIDE
5 months ago - InvestorPlace

RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis

•  Improvements demonstrated in all key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeks following once-daily oral treatment with RPT193 •  Further...

5 months ago - GlobeNewsWire

RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis

SOUTH SAN FRANCISCO, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

5 months ago - GlobeNewsWire

RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference

SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and ...

6 months ago - GlobeNewsWire

Implied Volatility Surging for RAPT Therapeutics (RAPT) Stock Options

Investors need to pay close attention to RAPT Therapeutics (RAPT) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

RAPT THERAPTICS (RAPT) Reports Q1 Loss, Misses Revenue Estimates

RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of -26.92% and -28.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research